Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) pipeline Target constitutes close to 45 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 5, 1, 20 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Metabolic Disorders, Oncology, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Respiratory, Genetic Disorders, Ophthalmology, Dermatology, Hematological Disorders, Infectious Disease and Women's Health which include indications Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Non-Alcoholic Steatohepatitis (NASH), Chronic Kidney Disease (Chronic Renal Failure), Huntington Disease, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Systemic Sclerosis (Scleroderma), Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Focal Segmental Glomerulosclerosis (FSGS), Friedreich Ataxia, Inflammation, Inflammatory Bowel Disease, Mitochondrial Myopathy, Neurodegenerative Diseases, Osteoarthritis, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Retinal Degeneration, Sickle Cell Disease, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes, Acne Vulgaris, Acute Renal Failure (ARF) (Acute Kidney Injury), Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), Age Related Macular Degeneration, Alport Syndrome, Asbestosis, Aspiration Pneumonitis, Atherosclerosis, Beta Thalassaemia, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Coronavirus Disease 2019 (COVID-19), Dementia, Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Epidermolysis Bullosa, Epilepsy, Fibrosis, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Idiopathic Pulmonary Fibrosis, IgA Nephropathy (Berger's Disease), Ischemia Reperfusion Injury, Ischemic Stroke, Juvenile Myelomonocytic Leukemia (JMML), Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), Kidney Disease (Nephropathy), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoporosis, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Polycystic Kidney Disease, Polycystic Ovarian Syndrome, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Fibrosis, Pulmonary Hypertension, Refractory Medulloblastoma, Retinopathy, Secondary Progressive Multiple Sclerosis (SPMS), Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease) and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Drugs In Development, 2022, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2 or NRF2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
• The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope